An evaluation of the efficacy of eptinezumab in the inpatient management of status migrainosus in comparison to intravenous lignocaine in patients who have failed other therapies

Status migrainosus is a severe, debilitating migraine that lasts for more than 72 hours and doesn't respond to standard treatments like triptans. It often requires hospitalisation. Currently, one of the main hospital treatments is a continuous intravenous infusion of lignocaine (a local anaesthetic), which can help break the migraine cycle but comes with its own risks and requires close monitoring. This trial is testing whether eptinezumab — a newer migraine-specific medication that works by blocking a protein called CGRP — could be a better or complementary option for these very difficult-to-treat migraines. Participants are randomly assigned to receive either eptinezumab or a placebo infusion upon hospital admission. All participants also receive standard hospital care. The study is double-blinded, meaning neither patients nor treating staff know who received which treatment, ensuring reliable results. You may be eligible if you are between 18 and 65, have had migraines for at least a year, and are currently experiencing a migraine lasting more than 72 hours that hasn't responded to triptan and chlorpromazine therapy. Several heart, liver, and neurological conditions, as well as pregnancy, may exclude you.